[Photo provided by Samsung Biologics Co.]
Samsung Biologics shares opened Monday session higher on news that the Korean biotech company recently won its patent invalidation trial against Lonza Group, a Swiss multinational biotech company, clearing a major hurdle to expanding its business to contract cell line development in China.
According to industry sources on Monday, Samsung Biologics filed a lawsuit in January this year, claiming that Lonza’s patents related to cell line development lack novelty and thus are not worthy of protection. China’s patent review board ruled in favor of Samsung Biologics on June 21. Cell line is a population of cells that can be maintained in culture with certain phenotypes and functions to be used as therapeutic antibody drugs.
The Kospi-trading shares gained 2.33 percent to close Monday at 1,009,000 won ($859.31).
The patent applied to some proteins that help cell line proliferation is Lonza’s family patent registered in China, which Samsung Biologics already invalidated in Korea in 2019.
With the ruling, Samsung Biologics will be able to strengthen its CDO business portfolio in China. The litigation was a preemptive measure to remove obstacle in the process of expanding Samsung Biologics’ CDO business in China, a company official said.
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]